For non-ST elevation acute coronary syndrome (NSTE-ACS). ANDA 206888, held by Gland. Tirofiban Hydrochloride.
As of Nov 16, 2026, ANDA 206888 (Tirofiban Hydrochloride), held by Gland, was first approved by FDA on Apr 8, 2021, with 0 approved supplements and 0 published complete response letters.
Tirofiban hydrochloride injection is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 8, 2021 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tirofiban HydrochlorideEQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML) · solution;intravenous | Tirofiban Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters